NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer

FORT WORTH (September 12, 2023) — NanOlogy LLC, a clinical-stage oncology company, announced today that two abstracts have been accepted for presentation at the ninth AACR Special Conference in Cancer Research: Pancreatic Cancer on September 27-30 in Boston, Massachusetts.

The first abstract (A048) entitled: “Enhancing the immune response in locally advanced pancreatic cancer (LAPC) with intratumoral endoscopic ultrasound-guided fine needle injection of large surface area microparticle paclitaxel.” will be presented by Andrew Hendifar (Cedars-Sinai Medical Center, Los Angeles, California) during poster session A on September 27th from 7:25 PM to 9:00 PM.

The second abstract (B004) entitled: “EUS guided local administration of large surface area microparticle paclitaxel with neoadjuvant chemotherapy in locally advanced pancreatic cancer: A single center experience.” will be presented by Harish Gopakumar (University of Illinois College of Medicine, Peoria, Illinois) during poster session B on September 28th from 4:40 PM to 6:30 PM.

A press release summarizing presentation data will be issued following the conference.

About NanOlogy
NanOlogy, LLC ( is a private clinical-stage oncology company formed in 2015 to improve the treatment of solid tumors with investigational drugs optimized for intratumoral delivery by a proprietary particle engineering technology platform. NanOlogy clinical programs have advanced investigational drugs in multiple solid tumors including pancreas, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers. The investigational drugs are covered by composition of matter patents issued in the US (US 9,814,685, US 10,507,195, US 10,993,927, and US 11,123,322), and other major jurisdictions worldwide, including Canada, Europe, Japan, China, South Korea, Australia, and India valid through June 2036. The composition patents form the foundation of an extensive intellectual property portfolio of over 130 issued patents protecting NanOlogy investigational drugs, formulations, methods, and technology.

Media Contact
Dan Eramian
Opus Biotech Communications